PDF herunterladen
Semin Thromb Hemost 2011; 37(5): 587-594
DOI: 10.1055/s-0031-1281047
© Thieme Medical Publishers

Diagnosis and Management of von Willebrand Disease: A Developing Country Perspective

Sukesh Chandran Nair1 , Auro Viswabandya2 , Alok Srivastava2
  • 1Department of Clinical Pathology and Blood Bank, Vellore, India
  • 2Department of Haematology at Christian Medical College, Vellore, India
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. November 2011 (online)

    Lizenzen und Reprints

ABSTRACT

Special challenges exist in the management of patients with von Willebrand disease (VWD) because of limitations in diagnostic facilities and therapeutic options. However, even within these limitations, it is possible to establish comprehensive services for this condition. Our data show that among 202 patients with VWD, 107 were type 3, 62 were type 1, and the others different categories of type 2. Basic tests such as bleeding time and activated partial thromboplastin time with factor (F)VIII coagulant are able to diagnose most of those with severe disease. We have been able to adapt the specific tests such as von Willebrand factor (VWF) ristocetin cofactor and VWF antigen from the tedious batched manual methods to cost-effective automated methods on advanced coagulometers. Discriminatory tests such as VWF collagen binding, VWF:FVIIIB, ristocetin-induced platelet agglutination (RIPA) are done in batches. Therapeutic options and for the treatment of bleeding include desmopressin, cryoprecipitate, and intermediate purity VWF-containing clotting factor concentrates. Tranexamic acid is also widely used as well as hormonal therapy for menorrhagia. We have also shown that modest doses of intermediate purity FVIII (Koate DVI; Talecris Biotherapeutics, Raleigh, NC, USA) at 35 IU/kg preoperatively and 10 to 20 IU/kg after that are sufficient for surgical hemostasis in these patients.

KEYWORDS

von Willebrand disease - developing countries - diagnosis - therapy

REFERENCES

  • 1 Nichols WL, Hultin MB, James AH et al.. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).  Haemophilia. 2008;  14 (2) 171-232
    Google Scholar
  • 2 Srivastava A. von Willebrand disease in the developing world.  Semin Hematol. 2005;  42 (1) 36-41
    Google Scholar
  • 3 Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries.  Semin Thromb Hemost. 2005;  31 (5) 569-576
    Google Scholar
  • 4 Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world.  Haemophilia. 2010;  16 (1) 20-32
    Google Scholar
  • 5 Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous venostasis bleeding time technique.  J Lab Clin Med. 1941;  26 1812-1822
    Google Scholar
  • 6 Koster T, Caekebeke-Peerlinck KM, Briet E. A randomized and blinded comparison of the sensitivity and the reproducibility of the Ivy and Simplate II bleeding time techniques.  Am J Clin Pathol. 1989;  92 (3) 315-320
    Google Scholar
  • 7 Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease.  Semin Thromb Hemost. 2009;  35 (1) 60-75
    Google Scholar
  • 8 Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000).  Blood Coagul Fibrinolysis. 2004;  15 (6) 505-511
    Google Scholar
  • 9 Sakthivel MSM, Nair SC, Srivastava A et al.. Ristocetin cofactor (VWF:RCo) assay—a comparison of a rapid automated method on ACL 10000 coagulometer and conventional aggregometry.  J Thromb Haemost. 2005;  3 (Suppl 1) P0868
    Google Scholar
  • 10 Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity.  Haemophilia. 2011;  17 (2) 252-256
    Google Scholar
  • 11 Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.  Blood Rev. 1999;  13 (4) 185-204
    Google Scholar
  • 12 Veyradier A, Fressinaud E, Sigaud M, Wolf M, Meyer D. A new automated method for von Willebrand factor antigen measurement using latex particles.  Thromb Haemost. 1999;  81 (2) 320-321
    Google Scholar
  • 13 Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen.  Thromb Res. 1986;  43 (3) 303-311
    Google Scholar
  • 14 Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.  N Engl J Med. 1980;  302 (19) 1047-1051
    Google Scholar
  • 15 Scott JP, Montgomery RR. The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the “neutral” monoclonal antibody binding assay.  Am J Clin Pathol. 1991;  96 (6) 723-728
    Google Scholar
  • 16 Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.  Am J Clin Pathol. 1998;  109 (3) 347-352
    Google Scholar
  • 17 Nishino M, Girma J-P, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII.  Blood. 1989;  74 (5) 1591-1599
    Google Scholar
  • 18 Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease—single center comparison of four different assays.  Thromb Haemost. 2000;  84 (6) 1127-1128
    Google Scholar
  • 19 Eikenboom J, Van Marion V, Putter H et al.. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD.  J Thromb Haemost. 2006;  4 (4) 774-782
    Google Scholar
  • 20 Sadler JE, Budde U, Eikenboom JC Working Party on von Willebrand Disease Classification et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.  J Thromb Haemost. 2006;  4 (10) 2103-2114
    Google Scholar
  • 21 Castaman G, Eikenboom JCJ, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation.  Thromb Haemost. 1999;  82 (3) 1065-1070
    Google Scholar
  • 22 Federici AB, Castaman G, Thompson A, Berntorp E. von Willebrand's disease: clinical management.  Haemophilia. 2006;  12 (Suppl 3) 152-158
    Google Scholar
  • 23 Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).  J Thromb Haemost. 2003;  1 (4) 682-689
    Google Scholar
  • 24 Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.  Blood Coagul Fibrinolysis. 2005;  16 (Suppl 1) S17-S21
    Google Scholar
  • 25 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.  Blood. 1997;  90 (7) 2515-2521
    Google Scholar
  • 26 Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility.  Thromb Haemost. 1987;  58 (4) 1033-1036
    Google Scholar
  • 27 Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States.  Haemophilia. 2004;  10 (2) 158-161
    Google Scholar
  • 28 Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates.  Haemophilia. 2004;  10 (3) 243-249
    Google Scholar
  • 29 Srivastava A, Mathews V, Bhurani D, Baidya S, Chandy M. Successful surgical hemostasis in patients with von Willebrand disease following infusion of KoateDVI.  Thromb Haemost. 2002;  87 (3) 541-543
    Google Scholar
  • 30 Viswabandya A, Mathews V, George B et al.. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.  Haemophilia. 2008;  14 (4) 763-767
    Google Scholar
  • 31 Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM. HAEMATE P Surgical Study Group . von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.  J Thromb Haemost. 2007;  5 (7) 1420-1430
    Google Scholar
  • 32 Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.  Haemophilia. 2007;  13 (2) 144-148
    Google Scholar
  • 33 Michiels JJ, Berneman Z, van der Planken M, Schroyens W, Budde U, van Vliet HHDM. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII/von Willebrand concentrate (Haemate-P).  Blood Coagul Fibrinolysis. 2004;  15 323-330
    Google Scholar
  • 34 Nossent AY, Dai L, Rosendaal FR, Vos HL, Eikenboom JC. Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis.  J Thromb Haemost. 2005;  3 (2) 405-407
    Google Scholar

Alok SrivastavaM.D. F.R.A.C.P. F.R.C.P.A. F.R.C.P. 

Department of Haematology

Christian Medical College, Vellore 632004, India

eMail: aloks@cmcvellore.ac.in